Iterum Therapeutics Provides Regulatory Update
While we are disappointed by this news, we continue to believe in the potential of sulopenemto help address the growing challenge of antibiotic resistance, said Corey Fishman, Chief Executive Officer of Iterum Therapeutics.
- While we are disappointed by this news, we continue to believe in the potential of sulopenemto help address the growing challenge of antibiotic resistance, said Corey Fishman, Chief Executive Officer of Iterum Therapeutics.
- Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.
- Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
- Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.